SCS Traditional denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for scs traditional are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Issues Duplicate-Therapy Denials for Traditional SCS

Humana may deny traditional spinal cord stimulation as "duplicate therapy" when records show a prior or concurrent pain-management intervention — such as an intrathecal drug delivery system, a prior SCS device, radiofrequency ablation, or ongoing high-frequency neuromodulation — that Humana's reviewers classify as addressing the same pain indication. The plan is effectively asserting that you are already receiving a treatment that serves the same clinical function.

## Why This Denial Is Appealable

Duplicate-therapy determinations are clinical judgments, not administrative ones, and they are subject to full appeal. Traditional SCS and other pain interventions differ in mechanism, target anatomy, and patient-response profile. If your physician determined that a prior or concurrent treatment is inadequate, has failed, or addresses a different component of your pain syndrome, that clinical distinction — documented in the chart — directly defeats the duplicate-therapy rationale. The denial must be reviewed on its clinical merits.

## Your Federal Appeal Rights

• Internal appeal: Under your plan's ERISA §503 procedures (employer plan) or Humana's individual/Medicare Advantage grievance process, you may file a written appeal with supporting clinical documentation.
• External review (ACA §2719): Duplicate-therapy denials based on clinical criteria are eligible for independent external review. The external-review request window is generally up to four months from the denial notice; confirm the deadline on your Explanation of Benefits.
• Expedited review: Request if your clinical situation is urgent.

## Documentation to Gather

1. Diagnosis and anatomy — documentation showing the specific pain generator, distribution, and diagnosis that the proposed SCS is targeting. 2. History and outcome of prior/concurrent treatments — dated records showing what the prior intervention did or did not achieve, including any objective functional or pain measures. 3. Clinical distinction letter — a letter from your implanting physician explaining how traditional SCS differs mechanistically from the prior treatment and why the prior treatment has not provided adequate relief for this specific indication. 4. Chart notes — recent office visits showing current symptom burden, functional status, and the physician's rationale for pursuing SCS rather than continuing or modifying existing therapy. 5. Humana coverage policy — request the specific Humana coverage policy number and version used in the denial; obtain the published text and map your documentation to each criterion.

## Criteria-Mapping Approach

Retrieve Humana's published medical coverage policy for spinal cord stimulation and any policy cited in the denial letter. For the duplicate-therapy issue, draft a section titled "Clinical Distinction" that quotes the policy's duplicate-therapy language, then cites chart evidence showing why traditional SCS represents a distinct and non-redundant intervention. Attach the treating physician's letter as a primary exhibit.